Long Term Effect of Oxaliplatin Treatment in Cancer Survivors

• Status: Completed
• Trial end date: 2019-08-29
• Target enrollment: 0
• Participant gender: All

Summary

This project will evaluate the neurotoxic effects of oxaliplatin. Oxaliplatin is considered the most neurotoxic chemotherapy, and at the origin of peripheral neuropathies. These neuropathies remain a problem in oncology because currently no prevention strategy has proved effective and only duloxetine seems to have a therapeutic benefit in improving symptoms. In the case of oxaliplatin, neuropathy forced oncologists to reduce the dose or to stop the chemotherapy, potentially degrading the oncological prognosis.

Objective of this study will be to assess, on a large number of patients (n> 500) who completed adjuvant chemotherapy (FOLFOX), the intensity of neuropathic disorders out of 5 years after the end of chemotherapy. Furthermore, this study should enable an assessment of the relationship between the intensity of neuropathy and comorbidities, such as anxiety and depression and health related quality of life of patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Treatments: Oxaliplatin

Criteria

Inclusion Criteria:

• • Living patient who received adjuvant chemotherapy (FOLFOX).

• Patient in remission.

• FOLFOX chemotherapy over for 0-5 years.

• Oral Non-opposition to participation in the study

Exclusion Criteria:

• • Patient unable to understand or respond to questionnaires.

• Age <18 years.

• Neurological diseases (eg Parkinson's disease, stroke, fibromyalgia ...).

• Legal incapacity (person deprived of liberty or under guardianship).